Professionals and Participating Hospitals


ARISTOCRAT: A randomised controlled phase II trial of temozolomide with or without cannabinoids in patients with recurrent glioblastoma 

For copies of the latest and previous versions of documents distributed for this trial, please contact the ARISTOCRAT Trial Office. 

Trial Overview

Overview of ARISTOCRAT trial
 Chief Investigator:  Professor Susan Short
 Sponsor:  University of Birmingham
 Funder:  The Brain Tumour Charity
 Disease Site:  Glioblastoma
 Trial Type:  Clinical Trial of an Investigational Medicinal Product
 Status:  Design
 EudraCT Number:  2021-005214-34
 IRAS Number:  1004427
 Anticipated Recruitment Start Date:  01-Sep-2022
 Anticipated Recruitment End Date:  01-Mar-2024
 CRCTU Trial Management Team:  Early Drug Development Team
 Trial Email Address: